QL1604 plus paclitaxel-cisplatin/carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trial.,Journal of Gynecologic Oncology

当前位置： X-MOL 学术 › J. Gynecol. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

QL1604 plus paclitaxel-cisplatin/carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trial.
Journal of Gynecologic Oncology ( IF 3.9 ) Pub Date : 2024-03-29 , DOI: 10.3802/jgo.2024.35.e77
Cheng Fang ₁ , Yun Zhou ₁ , Yanling Feng ₁ , Liping He ₂ , Jinjin Yu ₃ , Yuzhi Li ₄ , Mei Feng ₅ , Mei Pan ₆ , Lina Zhao ₇ , Dihong Tang ₈ , Xiumin Li ₉ , Buzhen Tan ₁₀ , Ruifang An ₁₁ , Xiaohui Zheng ₁₂ , Meimei Si ₁₂ , Baihui Zhang ₁₂ , Lingyan Li ₁₂ , Xiaoyan Kang ₁₂ , Qi Zhou ₁₃ , Jihong Liu ₁

Affiliation

Department of Gynecological Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Department of Gynecological Oncology Surgery, The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China.
Department of Gynecology, Affiliated Hospital of Jiangnan University, Wuxi, China.
Department of Gynecologic Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Department of Gynecological Radiation Oncology, Fujian Cancer Hospital, Fuzhou, China.
Department of Medical Oncology, Jiangxi Maternal and Child Health Care Hospital, Nanchang, China.
Department of Radiotherapy, The First Affiliated Hospital of Air Force Medical University, Xi'an, China.
Gynecological Oncology Department IV, Hunan Cancer Hospital, Changsha, China.
Department of Gynecology, Linyi Cancer Hospital, Linyi, China.
Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Department of Gynecology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Qilu Pharmaceutical Co., Ltd., Jinan, China.
Gynecological Oncology Center, Chongqing University Cancer Hospital, Chongqing, China.

QL1604 is a highly selective, humanized monoclonal antibody against programmed death protein 1. We assessed the efficacy and safety of QL1604 plus chemotherapy as first-line treatment in patients with advanced cervical cancer.

中文翻译：